Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Positive results is coming ....Get ready for blast off !!
http://www.bladdercancersupport.org/index.php?option=com_kunena&Itemid=114&func=view&catid=8&id=31827&limit=6&limitstart=12#31862
Re:Lowered dose BCG - so far so good 3 Months, 1 Week ago
Hi Alan
Bioniche is the sponsor of our Canadian bladder cancer network website.
www.cbcan.org
The trials are continuing in phase 111. Should have some preliminary results late this year.
Results comparing their product directly vs BCG will be a few years away.
Phase 111 trials are BCG refractory patients.
I can tell you that the people I know at Bioniche are extremely positive about their product.
When I hear more information I will post.
Ja
Positive results is coming ......
http://www.bladdercancersupport.org/index.php?option=com_kunena&Itemid=114&func=view&catid=8&id=31827&limit=6&limitstart=12#31862
Re:Lowered dose BCG - so far so good 3 Months, 1 Week ago
Hi Alan
Bioniche is the sponsor of our Canadian bladder cancer network website.
www.cbcan.org
The trials are continuing in phase 111. Should have some preliminary results late this year.
Results comparing their product directly vs BCG will be a few years away.
Phase 111 trials are BCG refractory patients.
I can tell you that the people I know at Bioniche are extremely positive about their product.
When I hear more information I will post.
Ja
This stock is ready to takeoff ..
Strong buy for Bioniche
http://www.nasd100.com/2010/08/bestrated-canadian-stocks-aug-1-2010.html
Top 100 Strong Buy Canadian stocks for August 1, 2010
Below are the top 100 Strong Buy Canadian stocks based on average Wall Street analyst ratings. Each analyst rating is assigned a number ranging from 1 to 5, with 1 being the highest rating (STRONG BUY) and 5 being the lowest rating (STRONG SELL). The average is calculated to represent the overall rating of a stock.
Ranking | Company | Average Rating Value | Average Rating
1 AlarmForce Industries (TSE:AF) 1.00 Strong Buy
2 Altius Minerals Corporation (TSE:ALS) 1.00 Strong Buy
3 Amorfix Life Sciences Ltd. (TSE:AMF) 1.00 Strong Buy
4 Aquila Resources Inc. (TSE:AQA) 1.00 Strong Buy
5 Aeroquest International Limited (TSE:AQL) 1.00 Strong Buy
6 Bioniche Life Sciences (TSE:BNC) 1.00 Strong Buy <<<<<<<<<<<<<<<<<
2 Approvals (BSD-2000 and MTX-180) within 2 Months !!!
BSD MEDICAL (BSDM)
Market Cap : 26 Million$
Cash : 8 Million$
Price : 1,05 $
About the MTX-180
The MTX-180 will work well, and will the be-all, end-all of the ablation market. Every doctor doing ablations will end up with one.
Remember BSDM has done it before, with the device they built for treating BPH. The TherMatrx100.
That device dominated the market, put Urologix (competitor) out of business, and became the system of choice when treating BPH. I believe BSDM sold the rights to it to American Medical Devices Inc. for about 40 million dollars, and that is how they have funded themselves, and the development of the MTX-180 over the last 5 years.
The MTX-180 should be, by all accounts, a cash cow that puts BSDM back on the map, and will draw much attention to their other more expensive hyperhtermia products.
MTX-180 is cheap (maybe 25,000 $$$ ?) but the replaceable parts for surgeries are $900-$3,200 PER SURGERY, and those parts will be sold by BSDM at a 50-60 percent margin. A "razor blade" business if you will.
You do the math.
If BSDM gets just one hundred MTX-180's out there, just 2 for every state in America, and each one does 5 ablations a day, 30 per week, that's 1,560 per year for each one. Multiply by 100 systems, that's, 156,000 ablations per year in the U.S. alone.
At $900-$3,200 x 156,000 you get 140 million to 561 million dollars in revenues generated in 1 year from 100 machines. That's some serious revenues! For a company with just 22 million shares outstanding!
Getting the picture now? What if they end up selling 500 MTX-180's???
Over 600 of the TherMatrx100 BPH treatment systems were sold in the last 6 years. BSDM can do it agian, and the MTX-180 is expected to dominate the marketplace and sell MORE.
MTX-180 could be all this company needs to get the stock into the double digits. Any sales from BSD-2000 is just gravy on top of the meat, the MTX-180.
All those revenues will now be spread out over just 23 million shares, 11 million of them closely held.
No debt, cash rich now (7.5 million $$) and a new product launch in 3Q. That is the reality. And don't forget, China is buying BSD-2000's, there is an ongoing clinical trial for Thermodox combined with the BSD-500, and the HDE submission for the BSD-2000 can be approved any day now.
This stock can triple in ONE day.
Phase 3 Data within 2 months
about urocidin ..12 min 30 sec ..listen
http://webcastingplayer.corporate-ir.net/player/playerHOST.aspx?c=123046&EventId=3228838&StreamId=1530678&TIK={e045afef-fae6-4f6c-bb2c-289b145e1274}&RGS=3&IndexId=
FDA Decision + Phase 3 Data in 3Q 2010
FDA approval for Econiche (E.coli Vaccine) & Urocidin (Bladder Cancer) Phase 3 results in 3Q 2010 !! Bioniche has tremendous upside Potential .Please do your own Homework.
Bioniche Has The Potential To Become The Next 10-Bagger .Good Luck to All !!!!!!
Bioniche Life Science (BNC.TO) or (BNHLF.PK) Canadian Stock !!
Market Cap: 74,6 Mio $
Cash: 22 Mio $
Price: 1,03 $
Dundee Sec with Buy-Rating (June 2010)....
Bioniche has three businesses with diversified risk/reward profiles:Animal Health, which is expected to generate around $28 million in salesin fiscal 2010; Human Health, with Phase 3 results expected in mid-2010from lead product, Urocidin, testing for bladder cancer; and FoodSafety, with Canadian approval and a conditional license pending in theU.S. of a vaccine for reducing E. coli 0157 in cattle feces, and apipeline of other vaccines.
Mr. Martin points out that Urocidin provides the “biggest upsidepotential” for Bioniche investors. His initial diligence suggests thatUrocidin has a “relatively high overall probability of approval,” eventhough the first of two planned Phase 3 trials has a moderate level ofrisk, as the refractory patients enrolled in the trial are a“tougher-to-treat” population than was enrolled in the Phase 2 trial, hesays.
Mitigating the risk somewhat is the 20% “complete response” hurdlerequired for Phase 3. That compares with the company’s Phase 2 results,where patients achieved a 46.4% CR rate at 26 weeks in a population thatwas mainly relapsed but also included a few patients being treated forthe first time.
A second planned Phase 3 trial will test Urocidin head-to-head againstthe current standard of care, baccilus Calmette-Guerin (BCG) infirst-line treatment, “where we expect Urocidin to demonstrate betterefficacy, based on prior data, and superior safety and tolerability,” hepredicts.
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to EndoPharmaceuticals. Based on incidence of bladder cancer and possiblepricing, he figures the global market opportunity for Urocidin in therefractory population could be $800 million. If the second Phase 3 trialexpands the Urocidin label to first-line treatment, the marketopportunity could grow to an estimated $2 billion.
“Twenty-five percent penetration of this market would represent $500million in annual sales and an estimated $112.5 million in gross profitfor Bioniche,” Mr. Martin says .
--------------------------------------------------------------------
Bioniche to Get up to $130M in Urology Deal with Endo
http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=51437
Crystal Research 18.02.2010
http://www.crystalra.com/pdf/BNC_2QFY10_Update_02-18-10.pdf
Urocidin Potential New Treatment for Bladder Cancer
http://www.associatedcontent.com/article/1939454/urocidin_potential_new_treatment_for_pg3.html?cat=70
Some Positive Signs ..
UPDATE 1-Bioniche gets $6 mln milestone payment from Endo Pharma
http://www.reuters.com/article/idUSBNG43432420091106
---
Bioniche obtains two additional milestones under licensing agreement with Endo
http://www.tradingmarkets.com/news/stock-alert/bnhlf_endp_bioniche-obtains-two-additional-milestones-under-licensing-agreement-with-endo-777521.html
--
All DMC (Data Monitoring Committee) are Positive !!!!
Bioniche Phase III Clinical Trial With Urocidin(TM) Given Continued Green Light By DMC
http://www.medicalnewstoday.com/articles/161677.php
Only 105 patients in current PIII !!!!
In November 2008,
during a meeting of urologists in Santigo Chile, the biopharmaceutical research company presented positive clinical studies (one and two) involving 130 bladder cancer patients treated with Urocidin. Elderly patients (average 73 years old) during the clinical studies noted excellent safety results .
Upcoming Milestones 2010
2009/2010 Conditional license for E. coli cattle vaccine in the U.S.
2009/2010 Achievement of pre-commercialization milestone payments for
UrocidinTM
2010 First U.S. sales of E. coli cattle vaccine
2010 Results of refractory Phase III bladder cancer trial
2011 Belleville, ON vaccine manufacturing centre operational
FDA approval for Econiche (E.coli Vaccine) & Urocidin (Bladder Cancer) Phase 3 results in 3Q 2010 !! Bioniche has tremendous upside Potential .Please do your own Homework.
Bioniche Has The Potential To Become The Next 10-Bagger .Good Luck to All !!!!!!
Bioniche Life Science (BNC.TO) or (BNHLF.PK) Canadian Stock !!
Market Cap: 74,6 Mio $
Cash: 22 Mio $
Price: 1,03 $
Dundee Sec with Buy-Rating (June 2010)....
Bioniche has three businesses with diversified risk/reward profiles:Animal Health, which is expected to generate around $28 million in salesin fiscal 2010; Human Health, with Phase 3 results expected in mid-2010from lead product, Urocidin, testing for bladder cancer; and FoodSafety, with Canadian approval and a conditional license pending in theU.S. of a vaccine for reducing E. coli 0157 in cattle feces, and apipeline of other vaccines.
Mr. Martin points out that Urocidin provides the “biggest upsidepotential” for Bioniche investors. His initial diligence suggests thatUrocidin has a “relatively high overall probability of approval,” eventhough the first of two planned Phase 3 trials has a moderate level ofrisk, as the refractory patients enrolled in the trial are a“tougher-to-treat” population than was enrolled in the Phase 2 trial, hesays.
Mitigating the risk somewhat is the 20% “complete response” hurdlerequired for Phase 3. That compares with the company’s Phase 2 results,where patients achieved a 46.4% CR rate at 26 weeks in a population thatwas mainly relapsed but also included a few patients being treated forthe first time.
A second planned Phase 3 trial will test Urocidin head-to-head againstthe current standard of care, baccilus Calmette-Guerin (BCG) infirst-line treatment, “where we expect Urocidin to demonstrate betterefficacy, based on prior data, and superior safety and tolerability,” hepredicts.
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to EndoPharmaceuticals. Based on incidence of bladder cancer and possiblepricing, he figures the global market opportunity for Urocidin in therefractory population could be $800 million. If the second Phase 3 trialexpands the Urocidin label to first-line treatment, the marketopportunity could grow to an estimated $2 billion.
“Twenty-five percent penetration of this market would represent $500million in annual sales and an estimated $112.5 million in gross profitfor Bioniche,” Mr. Martin says .
--------------------------------------------------------------------
Bioniche to Get up to $130M in Urology Deal with Endo
http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=51437
Crystal Research 18.02.2010
http://www.crystalra.com/pdf/BNC_2QFY10_Update_02-18-10.pdf
Urocidin Potential New Treatment for Bladder Cancer
http://www.associatedcontent.com/article/1939454/urocidin_potential_new_treatment_for_pg3.html?cat=70
Some Positive Signs ..
UPDATE 1-Bioniche gets $6 mln milestone payment from Endo Pharma
http://www.reuters.com/article/idUSBNG43432420091106
---
Bioniche obtains two additional milestones under licensing agreement with Endo
http://www.tradingmarkets.com/news/stock-alert/bnhlf_endp_bioniche-obtains-two-additional-milestones-under-licensing-agreement-with-endo-777521.html
--
All DMC (Data Monitoring Committee) are Positive !!!!
Bioniche Phase III Clinical Trial With Urocidin(TM) Given Continued Green Light By DMC
http://www.medicalnewstoday.com/articles/161677.php
Only 105 patients in current PIII !!!!
In November 2008,
during a meeting of urologists in Santigo Chile, the biopharmaceutical research company presented positive clinical studies (one and two) involving 130 bladder cancer patients treated with Urocidin. Elderly patients (average 73 years old) during the clinical studies noted excellent safety results .
Upcoming Milestones 2010
2009/2010 Conditional license for E. coli cattle vaccine in the U.S.
2009/2010 Achievement of pre-commercialization milestone payments for
UrocidinTM
2010 First U.S. sales of E. coli cattle vaccine
2010 Results of refractory Phase III bladder cancer trial
2011 Belleville, ON vaccine manufacturing centre operational
re BNC.TO will hit new highs very soon
Rally will start very soon
UPDATE
Puramed (PMBS.OB)
Market Cap 12 M$
Price 0,90 $
Shares Out: 13.3 M ...( 9 million shares held by insiders )
Float : 2,6 M
Presentation May 2010
http://www.puramedbioscience.com/PuraMed%20ppt-5.2010.ppt
Fact Sheet...PLEASE READ !!
http://www.puramedbioscience.com/PuraMed%20Corp%20Profile-4.2010.pdf
PuraMed BioScience, Inc. Chairman and CEO Russell Mitchell Writes to Shareholders
http://finance.yahoo.com/news/PuraMed-BioScience-Inc-pz-203664226.html?x=0&.v=1
Bid/Ask Data ..
http://www.otcmarkets.com/stock/pmbs/quote
UPDATE
USDA approval for Econiche (E.coli Vaccine) & Urocidin (Bladder Cancer) Phase 3 results in 3Q 2010 !! Bioniche has tremendous upside Potential .Please do your own Homework. Good Luck to All !!!!!!
Bioniche Life Science (BNC.TO) !!!
Market Cap: 74,6 Mio $
Cash: 22 Mio $
Price: 1,03 $
Buy rating by Dundee Sec (June 2010)....
Bioniche has three businesses with diversified risk/reward profiles:Animal Health, which is expected to generate around $28 million in salesin fiscal 2010; Human Health, with Phase 3 results expected in mid-2010from lead product, Urocidin, testing for bladder cancer; and FoodSafety, with Canadian approval and a conditional license pending in theU.S. of a vaccine for reducing E. coli 0157 in cattle feces, and apipeline of other vaccines.
Mr. Martin points out that Urocidin provides the “biggest upsidepotential” for Bioniche investors. His initial diligence suggests thatUrocidin has a “relatively high overall probability of approval,” eventhough the first of two planned Phase 3 trials has a moderate level ofrisk, as the refractory patients enrolled in the trial are a“tougher-to-treat” population than was enrolled in the Phase 2 trial, hesays.
Mitigating the risk somewhat is the 20% “complete response” hurdlerequired for Phase 3. That compares with the company’s Phase 2 results,where patients achieved a 46.4% CR rate at 26 weeks in a population thatwas mainly relapsed but also included a few patients being treated forthe first time.
A second planned Phase 3 trial will test Urocidin head-to-head againstthe current standard of care, baccilus Calmette-Guerin (BCG) infirst-line treatment, “where we expect Urocidin to demonstrate betterefficacy, based on prior data, and superior safety and tolerability,” hepredicts.
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to EndoPharmaceuticals. Based on incidence of bladder cancer and possiblepricing, he figures the global market opportunity for Urocidin in therefractory population could be $800 million. If the second Phase 3 trialexpands the Urocidin label to first-line treatment, the marketopportunity could grow to an estimated $2 billion.
“Twenty-five percent penetration of this market would represent $500million in annual sales and an estimated $112.5 million in gross profitfor Bioniche,” Mr. Martin says .
--------------------------------------------------------------------
Bioniche to Get up to $130M in Urology Deal with Endo
http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=51437
Crystal Research 18.02.2010
http://www.crystalra.com/pdf/BNC_2QFY10_Update_02-18-10.pdf
Some Positive Signs ..
UPDATE 1-Bioniche gets $6 mln milestone payment from Endo Pharma
http://www.reuters.com/article/idUSBNG43432420091106
---
Bioniche obtains two additional milestones under licensing agreement with Endo
http://www.tradingmarkets.com/news/stock-alert/bnhlf_endp_bioniche-obtains-two-a
dditional-milestones-under-licensing-agreement-with-endo-777521.html
--
All DMC (Data Monitoring Committee) are Positive !!!!
Bioniche Phase III Clinical Trial With Urocidin(TM) Given Continued Green Light By DMC
http://www.medicalnewstoday.com/articles/161677.php
Only 105 patients in current PIII !!!!
In November 2008,
during a meeting of urologists in Santigo Chile, the biopharmaceutical research company presented positive clinical studies (one and two) involving 130 bladder cancer patients treated with Urocidin. Elderly patients (average 73 years old) during the clinical studies noted excellent safety results .
Upcoming Milestones 2010
2009/2010 Conditional license for E. coli cattle vaccine in the U.S. <<<<<< HUGE MILESTONE
2009/2010 Achievement of pre-commercialization milestone payments for
UrocidinTM
2010 First U.S. sales of E. coli cattle vaccine
2010 Results of refractory Phase III bladder cancer trial <<<<<<<<<HUGE MILESTONE
2011 Belleville, ON vaccine manufacturing centre operational
re Phase III Data in July = Next Dendreon !!!!!!!
Some Positive Signs ..
1. Milestone :
UPDATE 1-Bioniche gets $6 mln milestone payment from Endo Pharma
http://www.reuters.com/article/idUSBNG43432420091106
---
2. Milestone :
Bioniche obtains two additional milestones under licensing agreement with Endo
http://www.tradingmarkets.com/news/stock-alert/bnhlf_endp_bioniche-obtains-two-a
dditional-milestones-under-licensing-agreement-with-endo-777521.html
--
3. Milestone :
All DMC (Data Monitoring Committee are Positive) !!!!
Bioniche Phase III Clinical Trial With Urocidin(TM) Given Continued Green Light By DMC
http://www.medicalnewstoday.com/articles/161677.php
---------------------------------------- --
Bioniche Life Science (BNC.TO) !!!
Market Cap: 73 Mio $
Cash: 22 Mio $
Price: 1 $
Buy rating by Dundee Sec (June 2010)....
Bioniche has three businesses with diversified risk/reward profiles: Animal Health, which is expected to generate around $28 million in sales in fiscal 2010; Human Health, with Phase 3 results expected in mid-2010 from lead product, Urocidin, testing for bladder cancer; and Food Safety, with Canadian approval and a conditional license pending in the U.S. of a vaccine for reducing E. coli 0157 in cattle feces, and a pipeline of other vaccines.
Mr. Martin points out that Urocidin provides the “biggest upside potential” for Bioniche investors. His initial diligence suggests that Urocidin has a “relatively high overall probability of approval,” even though the first of two planned Phase 3 trials has a moderate level of risk, as the refractory patients enrolled in the trial are a “tougher-to-treat” population than was enrolled in the Phase 2 trial, he says.
Mitigating the risk somewhat is the 20% “complete response” hurdle required for Phase 3. That compares with the company’s Phase 2 results, where patients achieved a 46.4% CR rate at 26 weeks in a population that was mainly relapsed but also included a few patients being treated for the first time.
A second planned Phase 3 trial will test Urocidin head-to-head against the current standard of care, baccilus Calmette-Guerin (BCG) in first-line treatment, “where we expect Urocidin to demonstrate better efficacy, based on prior data, and superior safety and tolerability,” he predicts.
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to Endo Pharmaceuticals. Based on incidence of bladder cancer and possible pricing, he figures the global market opportunity for Urocidin in the refractory population could be $800 million. If the second Phase 3 trial expands the Urocidin label to first-line treatment, the market opportunity could grow to an estimated $2 billion.
“Twenty-five percent penetration of this market would represent $500 million in annual sales and an estimated $112.5 million in gross profit for Bioniche,” Mr. Martin says .
Good news ...
This Stock is flying under Radar .Please do your own Homework . GlTA
PMBS Has The Potential To Become The Next 10-Bagger .
Puramed (PMBS.OB)
Market Cap 9,3 M$
Price 0,70 $
Shares Out 13,3 M --( 9 Million Shares held by Insiders )
Float : 2,6 M
Fact Sheet (Please Read)
http://www.puramedbioscience.com/PuraMed%20Corp%20Profile-4.2010.pdf
Presentation May 2010
http://www.puramedbioscience.com/PuraMed%20ppt-5.2010.ppt
Bid/Ask Data ...
http://www.otcmarkets.com/stock/pmbs/quote
Go To Market Timeline
1st Quarter 2010:
Ramp up media spend on the direct response commercial
Begin human trials on LipiGesic™ M
Begin retailer introduction to LipiGesic™ M
2nd Quarter 2010:
Continue to run the LipiGesic™ M direct response commercial
Begin retail introduction with individual retailer meetings and attend NACDS in June
Complete clinical trial transcript
Submit clinical trial results for publication
Complete product build of LipiGesic™ M for retailer roll-out
3rd Quarter 2010:
Publish clinical results in peer reviewed medical journal
Initiate PR effort to promote clinical trial results
Begin retail distribution nationally to U.S chain direct response drug stores and national drug wholesalers
Build initial LipiGesic™ PM inventory to make available for sale
Continue to run the LipiGesic™ M direct response commercial
4th Quarter 2010:
Initiate Phase II retail roll-out to include U.S. food and mass merchandiser channels
Start the production of the LipiGesic™ PM direct response commercial
Initiate production run of LipiGesic™ PM inventory for direct response campaign
On January 4, 2010, PuraMed announced that it had begun to generate revenue for the first time from launch of its direct response commercial featuring its leading product, LipiGesic™ M, a revolutionary non -prescription product to treat migraines. The former Master Broker for one of the world’s top selling non-prescription cold medicines, “Cold-EEZE®”, Russell Mitchell is now CEO of PuraMed BioScience. PuraMed engages in the research, development and marketing of non-prescription medicinal and healthcare products. Unlike prescription drugs or medications, non-prescription healthcare remedies such as PuraMed products do not require FDA approval. The Company uses a unique sublingual (under the tongue) delivery system utilizing the capillary structure under the tongue which is very close to the surface allowing for fast absorption and action. Sublingual delivery is also able to bypass the liver and digestive system which allows for smaller dosage requirements. PuraMed BioScience, Inc. emphasizes science as the key to success. For this reason, the Company believes its products will outperform other drugs currently available in the U.S.
PuraMed also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders, as well as LipiGesic™ H for common tension headaches. All three LipiGesic™ products are in liquid gel form and use the sublingual delivery system. Each of these also is effective and addresses a very large non-prescription consumer market, collectively well over $6 billion in the U.S. Each product will be unique in its class. Sales and marketing are the primary requirements for success. The Company does not require extensive personnel or infrastructure, relying instead on industry relationships, contractors, consultants, and third party manufacturers.
Bullish Chart
Must be out soon either Phase3 news or Econiche approval news are about to hit the wire.I'm feeling very optimistic . Let's get rolling.
Buy signal is created
http://www.barchart.com/quotes/stocks/BNC.TO
http://www.barchart.com/cheatsheet.php?sym=BNC.TO
http://www.nasd100.com/2010/07/bestrated-canadian-stocks-updated-jul-11-2010.html
Best-Rated Canadian Stocks Updated Jul 11, 2010
TOP 10 Lists; Up on Unusual Volume;Down on Unusual Volume;52-Week Highs; 52-Week Lows
Below are the best-rated Canadian stocksbased on average Wall Street analyst ratings.Each analyst rating is assigned a number ranging from 1 to5, with 1 being the highest rating (STRONG BUY) and 5 being thelowest rating (STRONG SELL). Then the average is calculated torepresent the overall rating of a stock.
Ranking | Company (Ticker) | Average Rating Value |Average Rating
1 Alarm Force Industries (TSE:AF) 1.00 StrongBuy
2 Altius Minerals Corporation (TSE:ALS) 1.00 Strong Buy
3 AmorfixLife Sciences Ltd. (TSE:AMF) 1.00 Strong Buy
4 Aquila Resources Inc. (TSE:AQA) 1.00Strong Buy
5 Aeroquest International Limited (TSE:AQL) 1.00 StrongBuy
6 Bioniche Life Sciences (TSE:BNC) 1.00 Strong Buy <<<<<< STRONG BUY <<<<<<<
Phase 3 Data within 2 Weeks !!!
Still a gigantic Opportunity !!
GOOD PHASE III RESULTS IS COMING VERY SOON !!
BNC IS READY TO TAKEOFF
http://ih.advfn.com/p.php?pid=webchart&symbol=TSE:BNC&period=0&size=19&volume=
Only 105 patients in current PIII !!!!
In November 2008,
during a meeting of urologists in Santigo Chile, the biopharmaceutical research company presented positive clinical studies (one and two) involving 130 bladder cancer patients treated with Urocidin. Elderly patients (average 73 years old) during the clinical studies noted excellent safety results
GOOD PHASE III RESULTS IS COMING VERY SOON !!
BNC IS READY TO TAKEOFF
http://ih.advfn.com/p.php?pid=webchart&symbol=TSE:BNC&period=0&size=19&volume=
Only 105 patients in current PIII !!!!
In November 2008,
during a meeting of urologists in Santigo Chile, the biopharmaceutical research company presented positive clinical studies (one and two) involving 130 bladder cancer patients treated with Urocidin. Elderly patients (average 73 years old) during the clinical studies noted excellent safety results
Good news ...
PuraMed BioScience Announces Completion of a Clinical Study of LipiGesic(TM) M
http://finance.yahoo.com/news/PuraMed-BioScience-Announces-pz-3454838394.html?x=0&.v=1
Last chance to get in cheap !!!!
5$++ soon
Phase III Data in July = Next Dendreon !!!!!!!
Urocidin (Bladder Cancer) Phase III Results within 4 Weeks .Lots will want this goldmine in the future. Please do your own Homework .
Bioniche Life Science (BNC.TO) or (BNHLF.PK) Canadian Stock !!!
Market Cap: 75 Mio $
Cash: 22 Mio $
Price: 1,03 $
Buy rating by Dundee Sec (June 2010)....
Bioniche has three businesses with diversified risk/reward profiles: Animal Health, which is expected to generate around $28 million in sales in fiscal 2010; Human Health, with Phase 3 results expected in mid-2010 from lead product, Urocidin, testing for bladder cancer; and Food Safety, with Canadian approval and a conditional license pending in the U.S. of a vaccine for reducing E. coli 0157 in cattle *****, and a pipeline of other vaccines.
Mr. Martin points out that Urocidin provides the “biggest upside potential” for Bioniche investors. His initial diligence suggests that Urocidin has a “relatively high overall probability of approval,” even though the first of two planned Phase 3 trials has a moderate level of risk, as the refractory patients enrolled in the trial are a “tougher-to-treat” population than was enrolled in the Phase 2 trial, he says.
Mitigating the risk somewhat is the 20% “complete response” hurdle required for Phase 3. That compares with the company’s Phase 2 results, where patients achieved a 46.4% CR rate at 26 weeks in a population that was mainly relapsed but also included a few patients being treated for the first time.
A second planned Phase 3 trial will test Urocidin head-to-head against the current standard of care, baccilus Calmette-Guerin (BCG) in first-line treatment, “where we expect Urocidin to demonstrate better efficacy, based on prior data, and superior safety and tolerability,” he predicts.
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to Endo Pharmaceuticals (ENDP 22.13 ?1.10%) (NASDAQ:ENDP). Based on incidence of bladder cancer and possible pricing, he figures the global market opportunity for Urocidin in the refractory population could be $800 million. If the second Phase 3 trial expands the Urocidin label to first-line treatment, the market opportunity could grow to an estimated $2 billion.
“Twenty-five percent penetration of this market would represent $500 million in annual sales and an estimated $112.5 million in gross profit for Bioniche,” Mr. Martin says.
BREAKOUT IS COMING ...
http://www.otcmarkets.com/stock/igxt/quote
BIG NEWS coming in june !!!
Markman hearing in june// If Positive = BIG BOOST FOR IGXT
300 Million US$ Market Potential for CPI-300 (antidepressant) approval in 4Q 2010 or early 1Q 2011 !!
Intelgenx (igxt.ob)
Market Cap 15 Mio$
Price : 0,45 $
In addition, we have a meeting scheduled with FDA in early June to address their complete response letter and clarify the required steps to obtain product approval. Finally, the Markman hearing in respect of the Biovail litigation is also scheduled for early June, and we remain optimistic for a positive outcome. The timing of this acquisition should yield substantial value to the company and its shareholders because we believe it is an excellent product that will become commercialized in the near future."
Objectives for the next 12 Months
?
Q2, 2010 Complete pilot study for ED film
?
Q2, 2010 Meet with FDA for CRL response (JUNE)
.
Q2, 2010 Markman hearing (Biovail litigation) (JUNE)
?
Q3, 2010 Complete pivotal migraine study
?
Q3/Q4, 2010 Respond to FDA CRL letter
?
Q4,2010 File ANDA antihypertensive product
?
Q1, 2011 Approval of CPI-300 NDA
Good News any day now .....
CPI-300 (Bupropion)
Status of NDA filing
•
Meeting with FDA in June 2010
•
Amendment to NDA with Pillar5 Pharma named as new manufacturer in 3Q 2010
•
Expect FDA decision 4Q 2010 / 1Q 2011
Status of BiovailLitigation
•
Biovail launched P-IV patent infringement suit on August 13, 2009
•
Case history demonstrates that Biovail has lost last 3 Wellbutrin patent litigation cases
•
Markman hearing scheduled for June 2010 <<<<<<<<<<<<<<<<<<<<<< could be a major price driver
Last chance to get in under 1$ ...
Big move over 1$ very soon ......
http://www.otcmarkets.com/stock/igxt/quote
Buy-Rating by U-Securities
Market cap of 16 Million$ is a Joke !!
Developments
Intelgenx has announced that they have been issued a patent by the U.S. Patent office (USPTO) for CPI-300, their
sustained release, high dose (450 mg) formulation of Bupropion HCl (Wellbutrin).
Impact
Positive. This solidifies Intelgenx as the Company all current sellers of Bupropion HCl have to negotiate with if
they would like the advantage of having a single dose pill.
Comments
The issuance of this patent puts Intelgenx in the position of having the only approved sustained release, high dose
one pill version of Bupropion HCL. This is very attractive to many existing sellers of generic Wellbutrin for several
reasons:
1. Doctors start patients at lower doses and then titrate them to higher doses. The compliance is higher when
patients take 1 pill versus 2 to 3 pills.
2. Intelgenx uses their proprietary VersaTab technology which can be produced at a significantly lower cost,
making the product more price competitive and profitable at the same time.
Intelgenx received a complete response letter from the FDA on February 8th, 2010, which provided 2 areas that
Intelgenx must address before approval:
1. Commercial manufacturing site: Intelgenx has hired Pillar5 to be their manufacturer and is now running the
necessary batches to gain FDA manufacturing approval. The Company believes that it will be finished
before Q4/2010.
2. Food Effect: The Company believes that this can be addressed through a label adjustment and a postapproval
educational effort. The food effect was observed both in CPI-300 and the reference product
(Wellbutrin). Intelgenx believes that they will have this issue resolved with the FDA in time for an H2/2010 filing and a possible Q4/2010 approval.
The patent issued by the USPTO strengthens Intelgenx’s position regarding any possible new entrants with a
similar dosage and puts them in a strong negotiating position for a commercialization partnership. However, the
current issues with Biovail are ongoing and will prevent Intelgenx from commercializing CPI-300. Intelgenx
believes that these issues could be resolved before final FDA approval in Q4/2010.
Valuation and Recommendation
Intelgenx has strengthened their negotiating position and is getting substantially closer to commercializing their
first major product. A successful approval and launch of CPI-300 will be a substantial revenue opportunity for
Intelgenx and will be strong proof of their technology and business model. This will greatly increase the value of
Intelgenx’s substantial 10 product pipeline. We are maintaining our recommendation with a Speculative Buy
and a target of $1.90
YIPPIIIIIIIIII
Approval in june = 4-5$+ per share !!!
RALLLLYYYYYYY
ALL I CAN SAY IS BUYYYYYYYYYYYYYYYYYYYYYYYYYY
Update. Do your own DD
IPCI is still significantly Undervalued . Please do your own Research .
FDA approval and Marketing Partner are next big Milestone in 2010 .
Very Bullish Chart ( Strong Buy - Rating)
http://www.barchart.com/quotes/stocks/IPCI
IntelliPharmaceutics (IPCI)
Market Cap: 30 Mio$
Price: 2,94 $
Shares Out: 10,9 M ... (CEO owns 6 Million Shares)
BioFianance Presentation April 2010
http://www.intellipharmaceutics.com/common/download/download.cfm?companyid=ABEA-43EQSZ&fileid=363699&filekey=cbd0c0e0-cd9e-43cf-a903-1e7fca66bdd9&filename=BioFinance%202010%20Toronto%20April%207.pdf
Big Pipeline
http://www.intellipharmaceutics.com/pipeline.cfm
More about IPCI
http://www.blackbusinessprofile.com/business-news/black-business-article/archive/2009/august/article/intellipharmaceutics-buys-biotech-drug-developer-vasogen/
2010 Milestones :
Potential FDA approval of FocalinXR
File and have accepted for review by the FDA, two additional ANDA applications
Establish at least one additional development/marketing alliance
Complete manufacturing of clinical batches of Rexista™
Complete Phase 1 studies using clinical batches of Rexista™
Schedule a pre-IND meeting with FDA to discuss Rexista™ clinical development plan
Intellipharmaceutics International Inc. (IPCI) engages in the research, development and commercialization of controlled-release drug technologies. The Company has 15 drug programs in development that address various therapeutic areas, including neurology, cardiovascular, Gastro-Intestinal Tract (GIT), pain and infection. Partnered with Par Pharmaceutical Companies Inc., the Company's lead drug product, a generic form of Focalin XR, is under review by the Food and Drug Administration for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Another one of the Company's leading drug candidate is Rexista, a competing drug to Oxycodone, developed to alleviate pain.
"With the development of its four leading drug products, including Generic Focalin XR, Generic Effexor XR, Rexista (Oxycodone) and Generic Coreg CR, the Company attempts to capture a portion of a combined market of more than $6.0 billion in annual revenue. Presently, revenue derived from its competitors' proprietary drugs Focalin XR, Effexor XR, Coreg CR and Oxycodone RX total $350 million, $3.9 billion, $300 million and $2.0 billion, respectively.
"The novel approach of manipulating the delivery of the above-named drug therapies via the Company's novel Hypermatrix(TM) concept allows the Company a margin of competitive advantage within the pharmaceutical space. Its Hypermatrix delivery system concept is designed to optimize Nature's hyper-dimensionality as it relates to drug therapies."
BSDM is on the move woohoooooo
long and strong on this one ...
Approval soon = 8-10$ per share
what a big opportunity ..
RALLLYYYYYYYYYYYYYYYYYYYYYYY
US Approval + Partner Deal is coming soon .......
2010 Milestones :
?Potential FDA approval of FocalinXR
?File and have accepted for review by the FDA, two additional ANDA applications
?Establish at least one additional development/marketing alliance
?Complete manufacturing of clinical batches of Rexista™
?Complete Phase 1 studies using clinical batches of Rexista™
?Schedule a pre-IND meeting with FDA to discuss Rexista™ clinical development plan
RAALLLLYYYYYYYYYYYYYYYYYYYYYY
IPCI is Still very very cheap
Better get in before its to late !!!!
3 Approvals within 1 Year = Excellent buying opportunity
Approval within 2 Weeks ????
Great buying opportunity here ...
Great News today ...Market cap of 24 Million$ is wayyyy undervalued !!!
Intellipharmaceutics Files ANDA With the FDA for Generic Protonix(R)
http://finance.yahoo.com/news/Intellipharmaceutics-Files-pz-3029377655.html?x=0&.v=1
"I am extremely pleased with the progress we continue to make with the advancement of our product pipeline," commented Dr. Isa Odidi, CEO of Intellipharmaceutics. "Protonix is the second ANDA we have filed with the FDA this year and, together with Focalin XR and Effexor XR, it represents another potential source of future revenue from our Company's ANDA pipeline."
PIII Data very soon .Market cap of 68 Million$ is way undervalued .
Bioniche has three businesses with diversified risk/reward profiles: Animal Health, which is expected to generate around $28 million in sales in fiscal 2010; Human Health, with Phase 3 results expected in mid-2010 from lead product, Urocidin, testing for bladder cancer; and Food Safety, with Canadian approval and a conditional license pending in the U.S. of a vaccine for reducing E. coli 0157 in cattle feces, and a pipeline of other vaccines.
Mr. Martin points out that Urocidin provides the “biggest upside potential” for Bioniche investors. His initial diligence suggests that Urocidin has a “relatively high overall probability of approval,” even though the first of two planned Phase 3 trials has a moderate level of risk, as the refractory patients enrolled in the trial are a “tougher-to-treat” population than was enrolled in the Phase 2 trial, he says.
Mitigating the risk somewhat is the 20% “complete response” hurdle required for Phase 3. That compares with the company’s Phase 2 results, where patients achieved a 46.4% CR rate at 26 weeks in a population that was mainly relapsed but also included a few patients being treated for the first time.
A second planned Phase 3 trial will test Urocidin head-to-head against the current standard of care, baccilus Calmette-Guerin (BCG) in first-line treatment, “where we expect Urocidin to demonstrate better efficacy, based on prior data, and superior safety and tolerability,” he predicts.
In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to Endo Pharmaceuticals (ENDP 21.47 ?0.42%) (NASDAQ:ENDP). Based on incidence of bladder cancer and possible pricing, he figures the global market opportunity for Urocidin in the refractory population could be $800 million. If the second Phase 3 trial expands the Urocidin label to first-line treatment, the market opportunity could grow to an estimated $2 billion.
“Twenty-five percent penetration of this market would represent $500 million in annual sales and an estimated $112.5 million in gross profit for Bioniche,” Mr. Martin says.
Markman hearing in june// If Positive = STOCK WILL EXPLODE
300 Million US$ Market Potential for CPI-300 (antidepressant) approval in 4Q 2010 or early 1Q 2011 !!
Intelgenx (igxt.ob)
Market Cap 15 Mio$
Price : 0,45 $
In addition, we have a meeting scheduled with FDA in early June to address their complete response letter and clarify the required steps to obtain product approval. Finally, the Markman hearing in respect of the Biovail litigation is also scheduled for early June, and we remain optimistic for a positive outcome. The timing of this acquisition should yield substantial value to the company and its shareholders because we believe it is an excellent product that will become commercialized in the near future."
Objectives for the next 12 Months
?
Q2, 2010 Complete pilot study for ED film
?
Q2, 2010 Meet with FDA for CRL response (JUNE)
.
Q2, 2010 Markman hearing (Biovail litigation) (JUNE)
?
Q3, 2010 Complete pivotal migraine study
?
Q3/Q4, 2010 Respond to FDA CRL letter
?
Q4,2010 File ANDA antihypertensive product
?
Q1, 2011 Approval of CPI-300 NDA